<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107391</url>
  </required_header>
  <id_info>
    <org_study_id>SP002</org_study_id>
    <secondary_id>2011-004986-34</secondary_id>
    <nct_id>NCT02107391</nct_id>
  </id_info>
  <brief_title>Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer</brief_title>
  <official_title>Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Combination With Hormone Therapy in Patients With Metastatic Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sotio a.s.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sotio a.s.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether DCVAC/PCa added onto hormone therapy can
      improve PSA progression times for patients with Metastatic Prostate Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of vaccine to improve Prostate Specific Antigen (PSA) levels.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with PSA Progression</measure>
    <time_frame>104 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Progression of Disease</measure>
    <time_frame>0, 6, 16, 28, 40, 52, 65, 78, 91, 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>0, 2, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 52, 65, 78, 91, 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Skeletal Related Events</measure>
    <time_frame>0, 2, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, 52, 65, 78, 91, 104 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life (QOL) assessed by EORTC QLQ-C30</measure>
    <time_frame>0, 16, 28, 40, 52, 52, 65, 78, 91, 104 weeks</time_frame>
    <description>European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) form C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pain assessed by EORTC QLQ-C30</measure>
    <time_frame>0, 16, 28, 40, 52, 52, 65, 78, 91, 104 weeks</time_frame>
    <description>Pain Scale from European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) form C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>DCVAC/PCA added Standard Hormone Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with Dendritic Cells DCVAC/PCa added on to a Standard of Care Hormone Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Hormone Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care Hormone Therapy as an Active Comparator Goserelin Acetate Leuprolide Acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dendritic Cells DCVAC/PCa</intervention_name>
    <description>Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy</description>
    <arm_group_label>DCVAC/PCA added Standard Hormone Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide acetate</intervention_name>
    <description>Standard of Care Hormone Therapy as an Active Comparator</description>
    <arm_group_label>Standard of Care Hormone Therapy</arm_group_label>
    <other_name>Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin Acetate</intervention_name>
    <description>Standard of Care Hormone Therapy as an Active Comparator</description>
    <arm_group_label>Standard of Care Hormone Therapy</arm_group_label>
    <other_name>Zoladex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male 18 years and older

          -  Histologically confirmed prostate adenocarcinoma

          -  Presence of bone or soft tissue metastasis (by CT or PET or MRI and/or scintigraphy)

          -  Androgen deprivation therapy using Luteinizing-hormone-releasing hormone ( LHRH)
             analogues commenced at least one month and at most three months prior randomization or
             orchiectomy performed at least one month and at most three months prior randomization

          -  Serum testosterone level at screening (≤ 1.7 nmol/l, resp. ≤ 50 ng/dL)

          -  Eastern Cooperative Oncology Group (ECOG) 0-2

        Exclusion Criteria:

          -  Confirmed brain and/or leptomeningeal metastases

          -  Prior or ongoing chemotherapy for prostate cancer

          -  Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater

          -  Other uncontrolled intercurrent illness

          -  Treatment with immunotherapy against prostate cancer

          -  Clinically significant cardiovascular disease

          -  Active autoimmune disease requiring treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Scheiner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sotio-Accord</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Jablonec nad Nisou</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jihlava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liberec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mnisek pod Brdy</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Biological</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Androgen Deprivation Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

